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INTRODUCTION
Vitiligo is a common idiopathic, acquired depigmentation
disorder caused by the selective destruction of melanocytes.
It affects 1-2% of the population with no predilection for
age, sex, or racial background. The disease is characterized
by circumscribed white spots on the skin that tend to enlarge
centrifugally over time or, less frequently, to recover sponta-
neously (1).
Traditional therapies include topical or systemic cortico-
steroids, PUVA (topical or oral psoralen followed by UVA irra-
diation), and narrow-band 311-nm UVB (NBUVB) photo-
therapy (2). NBUVB is now used frequently with satisfactory
results, although lesions in hard-to-reach areas like skin folds
often do not receive adequate exposure. Additionally, the abil-
ity to deliver high doses is often limited by phototoxicity to
both lesional and nonlesional skin.
The 308-nm excimer laser emits wavelengths adjacent to
those of NBUVB and is presumed to have similar biological
and clinical effects. This laser has been found to be effective
in the treatment of localized psoriasis, where it may offer ad-
vantages over NBUVB by sparing normal adjacent skin (3).
By allowing effective and selective targeting, this device also
reduces cumulative cutaneous UV burdens and reduces the
total number of treatments needed for clearing psoriasis. Spen-
cer et al. (4) recently reported that the 308-nm excimer laser
may also represent a new therapeutic option for the manage-
ment of vitiligo, resulting in repigmentation of vitiligo patch-
es in less time than that required with current modalities.
Previous studies have expounded on the safety and efficacy
of treatment with the 308 nm excimer laser, possibly even
more so than NBUVB phototherapy. However, these reports
involved comparisons of groups of patients, not direct compar-
isons within the same patient. The present study demonstrates
the greater efficacy of the 308-nm excimer laser treatment over
NBUVB phototherapy through comparisons of the treatment
effects on comparable patches within the same patient.
MATERIALS AND METHODS
Study population
Patients with generalized vitiligo (acrofacial or vulgaris
Seok-Beom Hong, Hyun-Ho Park,
Mu-Hyoung Lee
Department of Dermatology, College of Medicine,
Kyung Hee University, Seoul, Korea
Address for correspondence
Mu-Hyoung Lee, M.D.
Department of Dermatology, College of Medicine,
Kyung Hee University, 1 Hoeki-dong, 
Dongdaemun-gu, Seoul 130-702, Korea
Tel : +82.2-958-8512, Fax : +82.2-969-6538
E-mail : mhlee@khmc.or.kr
273
J Korean Med Sci 2005; 20: 273-8
ISSN 1011-8934
Copyright � The Korean Academy
of Medical Sciences
Short-term Effects of 308-nm Xenon-chloride Excimer Laser and 
Narrow-band Ultraviolet B in the Treatment of Vitiligo: 
A Comparative Study
We compared the clinical efficacy of a short-term intervention of 308-nm excimer
laser with that of narrow-band UVB (NBUVB) phototherapy for vitiligo patients to
see the early response. Twenty-three symmetrically patterned patches of vitiligo on
8 patients were selected. Vitiligo patches on one side of the body were treated 2
times per week for a maximum of 20 treatments with the excimer laser, and NBUVB
phototherapy was used on patches on the other side. Improvement (repigmentation)
was assessed on a visual scale via serial photographs taken every five treatments
and scored as follows: 0, ≤1% improvement; 1, ≤25% improvement; 2, 26-50%
improvement; 3, 51-75% improvement; and 4, ≥75% improvement. At five treat-
ments, the excimer laser-treated patches had an average score of 0.26, compared
with 0.04 for patches treated with NBUVB phototherapy. A slightly higher repigmen-
tation (p>0.05) in the excimer treated area was thus observed. At 10, 15, or 20 treat-
ments, the differences between the average scores were significant: 0.83, 1.17, and
1.39 for the excimer-treated patches, and 0.17, 0.30, and 0.74 for the NBUVB pho-
totherapy-treated areas (p<0.05). In conclusion, the 308-nm excimer laser appears
to be more effective than NBUVB phototherapy, as it produces more rapid and pro-
found repigmentation.
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type) were included in this study and were assessed for Fitz-
patrick skin phototypes, overall disease duration, and history
of previous therapy. Exclusion criteria included a history of
photosensitive disorder, skin cancer, and psychological disor-
ders. Eight patients (3 males, 5 females) were selected, and
all gave informed consent. Patient ages ranged from 29 to
58 yr (mean, 41.3 yr). Lesions on the genitalia or in the gluteal
crease were not treated. The treatment of subjects who had
undergone previous treatment was started after a wash-out
period of 2 weeks for topical steroids, 4 weeks for any form
of phototherapy, and 8 weeks for PUVA or immunomodu-
lating agents.
Selection of treatment sites
Twenty-three pairs of vitiligo patches which were symmet-
rically distributed on the 8 patients were selected for testing.
Vitiligo patches on the left side of the body were treated with
the 308-nm excimer laser, and patches on the right side were
treated with NBUVB phototherapy.
Light source
We used a 308-nm excimer laser with a self-contained gas
system of Xe-Cl (Photomedex
�, Carlsbad, CA, U.S.A.). Out-
put is initiated by a foot switch and consists of a train of short
pulses with a pulse-width of 30 nanoseconds, delivered through
a fiber optic hand piece. It is operated at 3 mJ per pulse with
pulse repetition of up to 200 Hz. The laser allows fixed flu-
ences to be delivered, from 100 mJ/cm2to a maximum dose of
2,100 mJ/cm2, in 50 mJ/cm2 increments. Additional fluences
can be delivered by pressing the foot switch. The NBUVB
phototherapy unit (Waldmann Co., Germany) contains a bank
of 48 fluorescent tubes (TL-100W/01, Phillips, Eindhoven,
The Netherlands) with peak emission at 311 to 312 nm.
Interventions
Therapy was administered twice per week on non-consec-
utive days, for a maximum of 20 treatments. In each session,
vitiligo patches on the left side were first with the 308-nm
excimer laser. The fluence administered was based on the
Friedman XTRAC-excimer protocol for the treatment of
vitiligo, in which the initial dose is determined by the site
of the lesion (Table 1), and the subsequent dose is determined
as follows: 100 mJ/cm2 increment if there is no erythema after
the initial treatment, 50 mJ/cm2 increment if there is erythe-
ma lasting for less than 24 hr, and no increment if there is ery-
thema lasting for 24 hr or more. If symptomatic erythema
(burning, pain) or blistering developed, treatment was with-
held until resolution, and then the dose was decreased by 50
mJ/cm2.
After each laser treatment, vitiligo patches on the right side
were treated with NBUVB phototherapy. Patches on the left
side of the body were shielded with gauze prior to treatment,
to avoid NBUVB exposure. The initial irradiation dose for
each patient was 250 mJ/cm2, and the dose was increased by
15% for each subsequent treatment. If the patient reported
mild erythema or pruritus, the irradiation dose was held con-
stant for the subsequent treatment, or until resolution of sym-
ptoms. If symptomatic erythema or blistering developed, the
dose was decreased by 15%.
Evaluation
Selected patches of vitiligo were photographed using stan-
dardized 35-mm color film before the first treatment, then
at five-treatment intervals until the completion of the study.
Improvement (repigmentation) relative to baseline was mea-
sured quantitatively on a visual scale by two independent in-
vestigators and graded as follows: grade 0, ≤1% improve-
ment; grade 1, ≤25% improvement; grade 2, 26-50% im-
provement; grade 3, 51-75% improvement; and grade 4,
≥75% improvement.
Statistical analysis
Student’s paired t-test was used to evaluate the difference
in repigmentation between the excimer-treated and NBUVB
phototherapy-treated areas. Statistical significance was defined
by a p value of less than 0.05.
RESULTS
Profile of patients
As shown in Table 2, the age range of the 8 patients was
29 to 58 yr, with a mean of 41.3 yr. Two of the eight patients
had skin phototype IV, and the rest had skin phototype V.
Disease duration ranged from 3 to 20 yr. Based on patient
histories, all previous therapies, which included topical and
systemic corticosteroids (n=7), PUVA (n=2), and NBUVB
(n=4), had failed in 6 of the 7 patients. In the present study,
all patients completed 20 treatments. None experienced any
adverse effects from the therapy that warranted discontinua-
tion of the treatment.
Initial dose 
(mJ/cm
2)
100 150 200 250 300 350 400 600
Site peri- face
orbital scalp arm hand finger
ear leg wrist elbow knee foot toe
neck trunk
axilla
Table 1. Friedman’s protocol for the treatment of vitiligo showing
the initial dose according to the site of the lesionTreatment outcome
The outcomes are presented in Table 3. In the excimer laser
treatment, the mean cumulative doses were 3.96 J/cm2 for
treating the face, 6.84 for the trunk, 4.07 for the extremities,
17.3 for the hands/feet, and 23.3 for the digits. In NBUVB
phototherapy, the mean cumulative dose was 12.17±0.34
J/cm2.
In this comparative study, the authors noted that the 308-
nm excimer laser produces more rapid and more profound
repigmentation, compared with NBUVB phototherapy (Fig.
1-3). In addition, in patients that did not respond to prior
treatment with conventional phototherapy including NBUVB,
repigmentation appeared (Fig. 4).
At the end of the study period the results were the follow-
ing. At five treatments, 6/23 (26%) vitiligo patches that re-
ceived the excimer laser treatment were evaluated as showing
grade 1 improvement; for NBUVB phototherapy, 1/23 (4%)
patches were classed as grade 1. At ten treatments, 13/23 (57
%) patches were grade 1, and 3/23 (13%) patches were grade
2 in the excimer laser-treated areas, while 5/23 (22%) patches
showed only grade 1 improvement in NBUVB photothera-
py-treated areas. At 15 excimer laser treatments, 9/23 (39%)
patches were grade 1, 6/23 (23%) were grade 2, and 2/23 (9
%) were grade 3. In NBUVB phototherapy-treated areas, 10/
23 patches showed grade 1 improvement. At 20 excimer laser
treatments, 6/23 (26%) patches were grade 1, 7/23 (30%)
were grade 2, and 4/23 (17%) were grade 3; of the NBUVB
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Patient 
No.
Skin type Site Type Duration (yr) Previous therapy
Sex/Age
(yr)
1 m/43 V Perioral, hand, finger Acrofacial 6 Topical steroid, NBUVB
2 m/29 V Perioral, cheek Acrofacial 3 Topical steroid, NBUVB
3 m/33 V Perioral, hand, foot, finger, toe Acrofacial 20 Topical and systemic steroid
4 f/33 V Neck, abdomen, leg Acrofacial 5 Systemic steroid, PUVA
5 f/56 V Neck Vulgaris 2 Topical steroid, NBUVB
6 f/53 IV Forehead, neck, hand, foot Vulgaris 10 Systemic steroid, PUVA
7 f/53 V Breast, abdomen Vulgaris 4 Topical steroid, NBUVB
8 f/30 IV Breast, abdomen, leg Vulgaris 3 None
Table 2. Profile of patients
Patient 
No.
Site
Repigmentation grade
×5
EN
Max. Fluence
of excimer
(mJ/cm
2)
Cumulative
dose of excimer
(J/cm
2)
Cumulative
dose of NBUVB
(J/cm
2)
×10
EN
×15
EN
×20
EN
1 Perioral 0 0 2 0 3 1 3 1 200 3.6 11.46
Hand 0 0 1 0 1 0 1 0 900 12.8 11.46
Finger 0 0 0 0 0 0 0 0 1,100 17.7 11.46
2 Perioral 0 0 1 0 1 0 2 1 150 2.1 12.36
Cheek 0 0 1 0 2 0 2 1 150 2.1 12.36
3 Perioral 0 0 1 0 1 1 1 1 150 2.7 12.36
Hand 0 0 0 0 0 0 0 0 1,500 20.6 12.36
Foot 0 0 0 0 0 0 0 0 1,750 22.8 12.36
Finger 0 0 0 0 0 0 0 0 2,100 24.5 12.36
Toe 0 0 0 0 0 0 0 0 2,100 27.6 12.36
4 Neck 0 0 1 1 1 1 1 1 200 2.3 11.76
Abdomen 1 0 1 0 2 1 3 2 350 4.3 11.76
Leg 0 0 1 0 1 0 2 1 600 5.8 11.76
5 Neck 0 0 1 1 1 1 2 1 800 9.7 12.36
6 Forehead 0 0 2 1 3 1 3 1 550 5.4 12.36
Neck 0 0 0 0 1 1 1 1 250 3.3 12.36
Hand 0 0 0 0 0 0 0 0 800 13.0 12.36
Leg 0 0 1 0 1 1 1 1 150 2.1 12.36
7 Breast 1 1 2 1 2 1 2 1 150 2.7 12.36
Abdomen 1 0 1 1 1 1 1 1 400 20.6 12.36
8 Breast 1 0 1 0 2 0 3 1 150 2.3 12.36
Abdomen 1 0 1 0 2 0 2 1 200 4.3 12.36
Leg 1 0 1 0 2 0 2 1 200 4.8 12.36
Table 3. Summary of results: repigmentation grade after X number of treatments
*E, excimer laser; N, NBUVB phototherapy.276 S.-B. Hong, H.-H. Park, M.-H. Lee
phototherapy-treated patches, 15/23 (65%) were grade 1, and
1/23 (4%) were grade 2.
We compared the average repigmentation scores of vitiligo
patches that received the excimer laser treatment with those
of NBUVB-treated patches at intervals of five treatments.
Improvement was seen with both modalities, but, starting
after ten treatments, significantly greater improvement was
apparent with excimer laser treatment (p<0.05) (Table 4).
The response rates of vitiligo lesions at various sites are given
in Table 5. For both treatment methods, the best response
was achieved with lesions located on the face and trunk. Lesions
located on the neck and extremities also responded with some
repigmentation, and one of the lesions located on a hand, foot,
or digit showed a response.
DISCUSSION
The recent report by Spencer et al. (4) has demonstrated
Fig. 1. Vitiligo patches on the left side of the trunk (A) prior to the
308-nm excimer laser treatment, (B) at 5 treatments, (C) at 15 treat-
ments, and (D) at 20 treatments (G: repigmentation grade).
A B
C D
G0
G2
G1
G3
Fig. 3. Vitiligo patches on the breast region (right side of line: NBU-
VB phototherapy-treated area, left side of line: excimer laser-treated
area) (A) prior to NBUVB phototherapy, (B) at 5 treatments, (C)a t
15 treatments, and (D) at 20 treatments (G: repigmentation grade).
A B
C D
Fig. 2. Vitiligo patches on the right side of the trunk (A) prior to
NBUVB phototherapy, (B) at 5 treatments, (C) at 15 treatments,
and (D) at 20 treatments (G: repigmentation grade).
A B
C D
G0
G1
G0
G2
G1 G0
G1 G1
G0
G2
G2
G2
Fig. 4. Vitiligo patches on the left side of the hand (A) prior to the
308-nm excimer laser treatment and (B) at 20 treatments. Vitiligo
patches on the right side of the hand (C) prior to NBUVB photother-
apy and (D) at 20 treatments.
A B
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some advantages of targeted phototherapy with the 308-nm
excimer laser, namely, the rapidity of onset of repigmentation
and the lower number of treatments needed to achieve satisfac-
tory repigmentation, compared with conventional NBUVB.
However, the benefits of the excimer laser over conventional
NBUVB have not been confirmed by a comparative trial in
individual patients.
In this comparative study, with the 308 nm excimer laser,
the authors noted an early appearance of repigmentation in
the majority of patients (17 of 23 vitiligo patches) compared
with NBUVB phototherapy (5 of 23) between treatment 5
and 10 (Table 3, Fig. 1-3). In addition, in patients that did
not respond to prior treatment with conventional photother-
apy including NBUVB, repigmentation appeared at 20 laser
treatments (Fig. 4). Table 4 shows that the average grade of
repigmentation in the excimer laser-treated patches was higher
than that in NBUVB-treated patches. It is not yet clear whe-
ther excimer laser treatment is more effective than NBUVB
phototherapy beyond 20 times laser or UVB irradiation. Be-
cause in conventional NBUVB it is not uncommon to see a
patient responding to treatment after more than 20 treatments,
when hardly any pigmentation was seen after 20 treatments.
The results of this study suggest that excimer laser treatment
may allow repigmentation within a shorter period of time
than does NBUVB phototherapy, while limiting exposure
to only selected areas. Also, the rapid onset of repigmentation
may play an important role in supporting patient motivation
and compliance.
Photobiologically, the wavelengths of the excimer laser (308
nm) and NBUVB (311 nm) are very close to one another, and
the therapeutic effects may well be similar. Recently, the me-
chanism of the excimer laser’s high efficacy in psoriasis treat-
ment has been investigated. Psoriasis vulgaris is mediated by
activated T-lymphocytes infiltrating the epidermis and the
dermo-epidermal interface (5). The major mechanism of action
of UVB light in the treatment of inflammatory dermatosis
is the cytotoxic effect on infiltrating T cells, where the mech-
anism of cell death is most probably apoptosis. The capacity
of a UVB light source to induce T cell apoptosis is paralleled
by its clinical efficacy (6, 7). Novak et al. (8) demonstrated
that the irradiation of T cells with the excimer laser in vitro
induced a higher number of apoptotic cells than did irradia-
tion with NBUVB light at the same dosage. The more effec-
tive induction of T cell apoptosis by the excimer laser may
be responsible for its greater clinical efficacy. The biological
effects of coherent laser light may differ from those of incoher-
ent light of the same wavelength. Conventional UVB sources
emit polychromatic, continuous, incoherent light, whereas
the excimer laser emits coherent, monochromatic, UVB light
in short pulses. This permits the variation of some important
phototherapeutic parameters, such as impulse frequency and
intensity. It has been suggested that these optical properties
of the excimer laser should make it more effective than NBU-
VB in the treatment of vitiligo (9).
The results of this study strongly support targeted photo-
therapy with the xenon-chloride 308-nm excimer laser as more
effective than NBUVB phototherapy in the treatment of vitili-
go. Long-term studies are needed to confirm and extend these
findings.
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